VIDEO: Study investigates using probiotic agent with standard renal cell carcinoma therapy
Click Here to Manage Email Alerts
In this video, Sumanta K. Pal, MD, discusses updates from a clinical trial on the use of nivolumab/ipilimumab with and without a probiotic agent in patients with metastatic renal cell carcinoma.
The study was presented at the 2022 ASCO Genitourinary Cancers Symposium.
Pal, who is co-director of Kidney Cancer Program at City of Hope, and a HemOnc Today Editorial Board Member, explained that the trial examined “a regimen of [nivolumab/ipilimumab]... a standard front-line regimen for renal cell carcinoma with or without the probiotic agent CBM588.”
He noted that the probiotic agent is a “live bacterial product that we think really fortifies the gut, increases the presence of bifidogenic species and other species that we think would really sort of enhance the microenvironment within the gut and possibly augment the antitumor immune response.”
Collapse
Read more about
Click Here to Manage Email Alerts